Compare Imperial Oil Limited Common Stock (IMO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Imperial Oil Limited Common Stock vs Mesoblast Limited — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Mesoblast Limited trades at $13.76 (market cap $1.83B). The key difference: Imperial Oil Limited Common Stock is far larger — about 34× Mesoblast Limited's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| IMO | MESO | |
|---|---|---|
Market Cap | $62.22B | $1.83B |
Volume | 560,544 | 259,445 |
Sector | Energy | Health |
52-Week High | $138.33 | $20.96 |
52-Week Low | $83.72 | $13.19 |
Enterprise Value | $63.13B | $1.91B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 15 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Imperial Oil Limited Common Stock
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
